Healthpoint plots $60M FW expansion, new hires; AstraZeneca and Karolinska set up translational research center;

 @FierceBiotech: See the faces of biotech leaders at BIO2012 in our convention slideshow. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Interesting to note that if the ACA is tossed out by the Supremes, there goes 12 years of exclusivity for biologics and biosimilars pathway. Poof. | Follow @JohnCFierce

 @RyanMFierce: My take from BIO 2012 on how the pharma herd faces hurdles with pricey new drugs. Report | Follow @RyanMFierce

> Healthpoint Biotherapeutics says it will invest $60 million on research and manufacturing facilities in Fort Worth while adding 51 workers to its staff. The company produces skin and wound care products. Story

> AstraZeneca is contributing $4.5 million to set up a new translational research center at the Karolinska Institutet in Stockholm. Release

> Metaclipse Therapeutics, a spinoff of Emory University, is raising $2.5 million to support its work on new cancer therapies. Story

> Alnylam Pharmaceuticals says it has received orphan drug status for ALN-TTR02, its therapy for rare cases of TTR-FAP. Story

Pharma News

 @FiercePharma: AstraZeneca's Brilinta = lower healthcare costs, even at brand prices, finds cost-based analysis of PLATO data. More | Follow @FiercePharma

> Celgene's hopes for Revlimid stymied by regulatory setback. Story

> J&J close to $1.5B-plus Risperdal settlement, but not there yet. Article

> Is Madagascar 3's friendly lion a dangerous drug spokesman? More

> Anti-overtime ruling a disguised blessing for reps, recruiters say. Report

Medical Devices News

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: EndoGastric pulled in another $13M in new venture finding for a device designed to help treat chronic acid reflux. Press release | Follow @MarkHFierce

 @DamianFierce: Lawmakers, device industry on the same page as FDA user fee clears House, moves toward adoption. Article | Follow @DamianFierce

> House votes to extend medical device user fees. More

> Roche Diagnostics commits $300M to Indianapolis expansion. Story

> United Arab Emirates invests in med device tech for school clinics. Item

Pharma Manufacturing News

> Shasun cutting costs with Indian intermediates plant. Article

> Bard, Sartorius invest nearly $70M in Puerto Rico plants. Story

> CSL confirms convulsions appear tied to Fluvax manufacturing. More

Vaccines News

> HPV DNA vax should enter the clinic in 2013. More

> Therapeutic cancer vaccines: Optimism for the future at BIO2012. Article

> Anthrax vax to move into new Phase II trials. Story

> Genocea's HSV-2 vax to hit the clinic. News

CRO News

 @NesaNFierce: Not shocked that the Philippines and Indonesia are eyed as emerging leaders in outsourcing. Population means a lot. More | Follow @NesaNFierce

> Can Russia emerge as a global biotech and manufacturing leader? More

> Filling services help Dalton seal manufacturing deal with Clarity. Article

> Biopharma looks at pros and cons of CMOs when debating in-house versus outsourcing. News

And Finally… Mount Sinai Medical Center has begun using the radioactive agent florbetapir (otherwise known as Eli Lilly's Amyvid) to help confirm, or rule out, Alzheimer's disease. Release

 

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.